Navigation Links
GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant

ST. JOSEPH, Mich., Feb. 13 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that they will be collaborating with The Netherlands Toxicogenomics Center (NTC). This 5 year, 25 Million Euro, multi-party program will use toxicogenomics to develop highly predictive 'omics-based screens, to be used for the in depth evaluation of chemical safety for human health, replacing, reducing or refining animal experiments, and improving the scientific basis of chemical risk assessment.

The NTC will use GeneGo's MetaCore and MetaDrug systems biology data analysis platform to coordinate, visualize and interpret chemical, metabolomic, proteomic and gene expression data generated by the project members, and to identify the key biological functions and pathways contributing to the adverse effects of xenobiotic exposure. GeneGo will further contribute by working within the bioinformatics workgroup of the NTC to build predictive models, using GeneGo's "Functional Descriptor" technology, for the earlier identification of adverse effects in animals from short-term in vivo experiments, or from in vitro experiments using cells in place of animals.

Professor Jos Kleinjans, Director of the NTC said "having GeneGo as a partner in the project, and having access to their leading systems biology data visualization and analysis tools and expertise, will help us to derive the best value from the data we are generating and make progress in the application of an integrated systems toxicology approach to risk assessment."

Dr. Richard Brennan, Director of Toxicology at GeneGo, said, "We are delighted to be a part of this exciting and ambitious project. The tools we have developed at GeneGo are an excellent solution for analyzing the multiple data types that will be generated by the NTC members and for understanding the biological basis of chemically-induced toxicity. The project will help us to further validate and develop our capabilities in predictive systems toxicology."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.6(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.6(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at

MetaCore(TM), MetaBase(TM) MetaDrug(TM) , MetaLink(TM), MetaDiscovery(TM), MetaTox(TM) , MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GSK Extends GeneGo License and Adds New Products
2. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
3. GeneGo Integrates With Cytoscape
4. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
5. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
6. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Millstone Medical Outsourcing Relocates Memphis Distribution Center Within 72 Hours of Tornado Disaster
9. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
10. The Centers for Disease Control & Prevention Signs Vaccine Storage and Distribution Contract with Sentry Logistic Solutions
11. Tom Shaws NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... , November 25, 2015 Studies ... and human plaque and pave the way for more effective ... in cats     --> ... commonly diagnosed health problems in cats, yet relatively little was ... Two collaborative studies have been conducted by researchers from the ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):